Day and thank you for standing by. Welcome to Keenova's first quarter 2026 earnings announcements conference call. At this time, all participants are in a listen -only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Gerard Meuchner. Sir, please go ahead. Thank you, operator. Welcome everyone. Before we begin, let me remind you that we will make forward-looking statements on this call, and actual results may differ materially from those expressed or implied in these statements. These statements are made as of today, May 12, 2026. We undertake no obligation to update them except as required by law. Please refer to our SEC filings for a detailed discussion of the risks and uncertainties affecting our business. We will also reference certain non-GAAP financial measures on this call. Reconciliations to the most directly comparable GAAP measures are included in our earnings release and in the investor presentation available on the investor relations section of our website at ir.mallinckrodt.com. We use our website as a channel to distribute important and time-critical company information. You should look to the investor relations page of the website for this information. As noted in our earnings release on July 31, 2025, the company completed its merger with Endo, and on November 10, 2025, it completed the separation of Par Health. The financial results presented on today's call and in our presentation reflect Keenova's continuing operations. The comparable first quarter 2025 results presented today were prepared on a pro forma basis as if the merger and separation had each occurred at the beginning of 2025. Pro forma combined results for the first quarter 2025 also exclude Endo's international pharmaceuticals business, which was sold in 2025. Joining me on today's call are Sigurdur Olafsson, our President, Chief Executive Officer, and Christiana Stamoulis, our President and Chief Financial Officer. I'll now turn the call over to Siggi. Thanks, Gerard. Good morning, everyone. As our first quarter 2026 results show, we continue to build the positive momentum at Keenova. Our strong execution helped to drive first quarter performance ahead of our expectations with double-digit top-line growth and significant adjusted EBITDA expansion in the quarter, mainly reflecting strong growth in our core brands, Acthar Gel and XIAFLEX. We continue to invest in these brands, both clinically and operationally, and we'll provide additional details of that work later in the call. We also continue to maximize the contribution from our established brands. Of particular note, TERLIVAZ grew 42% as the breadth and depth of the prescriber base continue to expand. In addition, the INOmax product line continues to stabilize, with EVOLVE placements in the U.S. totaling 1,196 as of March 31 versus 945 at the end of 2025, while Japan continues to generate double-digit growth for INOmax. A result of our overall performance in the first quarter, we are reaffirming the full -year guidance we announced on March 31 as we prepare to pursue the listing of Keenova's ordinary shares on the New York Stock Exchange in the second half of 2026, subject to board approval and other considerations and conditions. We also remain on track to achieve $150 million of annual pre-tax run rate synergies by the third anniversary of the merger. Let's turn to slide six to provide an update on our pipeline specific to XIAFLEX. We continue to invest in research and development to pursue promising opportunities for this core brand and to accelerate its long-term growth profile. Today, we can report that we expect to receive top-line results from the phase III plantar fibromatosis study in July 2026. Patient enrollment for the phase III study was completed earlier this year, and we are targeting regulatory submission in the fourth quarter of 2026. We believe that approximately 300,000 Americans are diagnosed with plantar fibromatosis at any given time. Specific to hammertoe, you may remember that we reported on March 31 that our proof of concept study evaluating XIAFLEX for hammertoe met its primary safety endpoint and secondary exploratory efficacy endpoints. The top-line data demonstrating a favorable safety profile. We have a meeting with the FDA in June to discuss this program. We are on track for patient enrollment for the phase III HAMLET-0 study to start in the third quarter of 2026. We are excited by the potential to bring XIAFLEX to podiatry patients with unmet needs. With that, I'll turn the call over to Christiana. Thank you, Siggi. Good morning, everyone. Before reviewing our results, I want to reiterate that the first quarter 2026 financial results presented on this call and in our presentations reflect Keenova's continuing operations and that the 2025 results were prepared on a pro forma combined basis to facilitate a consistent year-over-year comparison. Moving to our first quarter 2026 financial results on slide seven. Net sales were $468 million in the first quarter, an increase of 20% compared to the prior year period, driven by strength in Acthar Gel and XIAFLEX. Adjusted EBITDA was $174 million, primarily driven by the growth in Acthar Gel and XIAFLEX, and the contribution of synergies, and partially offset by increased investment in our core brands. Let's now take a closer look at the key drivers of our performance, starting with Acthar Gel. Net sales for Acthar Gel in the first quarter of 2026 were $170 million, representing an increase of 47% compared to net sales of $115 million in the first quarter of 2025. This marks the ninth consecutive quarter of growth for Acthar Gel. We are seeing robust patient demand for this product across all therapeutic areas, reflecting investments in expanding the sales force. Our commercial investments, combined with strong execution, have helped to drive greater category awareness and expansion. We also see continued momentum in the uptake of our innovative SelfJect device, which helped Acthar Gel achieve an all-time high in new patient starts in this first quarter. In addition to market expansion and the continued adoption of SelfJect, year-over-year growth also benefited from improved patient access. As shown in this chart on slide nine, which illustrates Acthar net sales for 2024, 2025, and the first quarter of 2026, the impact of enhanced access became more visible beginning in the second quarter of 2025. As a result, the comparison of Q1 2026 to the prior -year period is, again, a quarter that did not yet reflect this access improvement. Looking ahead, we expect enhanced access to continue supporting patient demand, though it is not expected to be a significant driver of year-over-year growth for the remainder of the year. Turning now to XIAFLEX. Net sales for XIAFLEX in the first quarter of 2026 were $134 million, an increase of 11% compared to net sales of $121 million in the first quarter of 2025, when the product was owned by Endo. Growth was driven primarily by higher pricing and increased demand in Peyronie's disease. We continue to leverage direct-to-consumer advertising to raise awareness of Peyronie's disease and Dupuytren's contracture, which we believe will help drive XIAFLEX demand for both indications. This month, we began rolling out a new awareness campaign for Dupuytren's contracture as part of our broader direct-to-consumer strategy, which also includes a new digital campaign focused on Peyronie's disease that began rolling out in February. We expect to continue to see the benefits from these efforts throughout the year. Turning to slide 11, we want to provide a quick update on our synergies efforts and our balance sheet. As mentioned earlier, we remain on track to achieve $150 million of annual pre-tax run rate synergies by the third anniversary of the merger. In the first quarter, we achieved $23 million of our planned $100 million of synergies this year. Additionally, we ended the first quarter with a strong balance sheet that supports continued investment in driving long-term growth. At quarter end, we had approximately $100 million-$825 million of cash and cash equivalents and $2.478 billion of total debt outstanding, representing a net debt to covenant -adjusted EBITDA ratio of approximately 1.87x. Lastly, let's turn to our guidance. For the full year 2026, we are reaffirming the guidance we issued on March 31, 2026, which is as follows. Net sales of Acthar Gel to grow in the mid-teens. Net sales of XIAFLEX to grow in the mid- to high single digits. Total net sales of $1.94 billion-$2 billion. Adjusted EBITDA of $730 million-$760 million, which includes the anticipated 2026 merger synergies. We expect that Acthar Gel patient demand will again be driven by SelfJect uptake and category awareness expansion, supported by commercial investments, and we expect XIAFLEX demand to be supported by heightened patient awareness. I will now hand the call back to Siggi for closing remarks. Thank you, Christiana. Our first -quarter performance reinforces our confidence in the bright future of Keenova. We believe that the strength of our core brands, supported by targeted pipeline expansion and the effort to maximize the value of our established brands, will drive sustainable revenue growth and margin expansion over time. As always, our capital deployment decisions will reflect a rigorous return framework, prioritizing opportunities that support durable growth, enhance cash flow generation, and create long-term shareholder value. As we conclude today's call, I want to express my gratitude to our team and their commitment to serving the patients who really rely on us. With that, I open it up for Q&A. Thank you. As a reminder, to ask a question, please press star-one-one on your telephone and wait for your name to be announced. To withdraw your question, please press star-one-one again. We ask that you please limit yourself to one question and one follow-up. One moment while we compile our Q&A roster. Our first question comes from the line of Pranav Srinivasan with Diameter Capital Partners. Your line is open. Please go ahead. Hey, Siggi. Hey, Christiana. Congrats on a really nice quarter. I've got two questions, one on Acthar and then one on BD. On Acthar first, obviously a really good quarter, yet I guess reaffirming the full -year guide. I appreciate the fact that maybe we'll start seeing some tougher comps, starting the second quarter. My understanding is the market is still growing. How should we kind of reconcile market growth versus the added sales reps that you guys have brought into the market this year, along with the guide? Maybe if it's fair to think, with some of those puts and takes, there's still maybe some upside to the guide. I've got one follow-up. Thanks. Yes. Hi, thank you for your question. Acthar, as you saw, the Q1 performance was very strong, driven by the three drivers I mentioned on the call. The overall market expansion, the SelfJect adoption, and also this quarter we are continuing to see the benefit from the improved access when compared to last quarter this year, last year, and Q1 last year, when that benefit was not yet reflected. The guidance that we have provided for the full year, the mid-teens growth rate, reflects that continued market expansion, the SelfJect adoption. As we showed on slide nine, we don't expect to see additional growth driven by the improved patient access, given that the rest of the year is compared to last year's Q2 through Q4, where there was already that benefit reflected in the numbers. That's why the overall growth is coming down to the average of mid-teens that we have indicated, even though we are continuing to grow with the market. Got it. Okay. Makes sense. I guess the added sales reps that you guys are bringing into the market this year for Acthar shouldn't that be a tailwind as well as we progress through the year? Yeah. It's a good question. The thing is we're having sales reps at the moment, and usually what you see when you add the sales force to your team is you really see the benefits starting six to nine months after they join. You know, it takes time for training and getting them into the right setting. The benefit will come later on. You don't see the initial benefit from the additional investment. That would more be, you will see more of that benefit in 2027. Got it. Makes sense. Okay. Just to pivot gears, one last question on BD. Any update you guys can share on sale of Percocet? Anything else in the portfolio you guys are looking to prune? Maybe anything on the M&A pipeline as well. As we indicated last quarter, we are exploring the divestiture of Percocet. Those discussions are ongoing, and at this time we don't have any updates. On the BD front, we are looking for assets that would fit well with our current capabilities so that we'll be able to leverage the commercial infrastructure that we have in place. Assets that are commercial stage that play in the areas where we are currently in. At this point, we don't have any update. Any potential future pruning of the established trade products will come following any introduction of new work drivers to the portfolio. Thanks, guys. Thank you. I would now like to hand the conference back over to Gerard Meuchner for closing remarks. Thank you. Thanks, Siggi and Christiana. Thanks all of you for joining us today. We look forward to engaging with you in the days and weeks ahead. If you have questions, the best way to contact us will be via email, and we will work to get back to you as soon as possible. Thanks again, and have a good day. This concludes today's conference call. Thank you for participating, and you may now disconnect.